Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 17INDUSTRY 3NETWORK 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 3Dermatologic 3Gastrointestinal 2Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Pancreatic Neoplasms 13Neoplasm Metastasis 10Neoplasms 8Lung Neoplasms 6Colorectal Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Melanoma 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic cancer, adult 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Pancreatic Cancer Non-resectable 1Pancreas Adenocarcinoma 1

Interventions

pembrolizumab 126Cisplatin 47Cetuximab 46Nivolumab 36Carboplatin 33Paclitaxel 28Fluorouracil 26Docetaxel 17avelumab 11Radiotherapy 11Cyclophosphamide 11cemiplimab 10atezolizumab 10durvalumab 9Ipilimumab 8spartalizumab 7budigalimab 7Gemcitabine 7Capecitabine 7tremelimumab 6lenvatinib 6fludarabine 6Pemetrexed 6epacadostat 5Fulvestrant 5130-nm albumin-bound paclitaxel 5zimberelimab 4tislelizumab 4Trastuzumab 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Squamous Cell Carcinoma of Head and Neck × Taxes × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04083599 2026-05-06

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
350 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡